As mast cells have been highlighted in the pathogenesis of diarrhea-predominant irritable bowel syndrome, a new term "mastocytic enterocolitis" was suggested by Jakate and colleagues to describe an increase in mucosal mast cells in patients with chronic intractable diarrhea and favorable response to treatment with antihistamines. Although it is not an established disease entity, two cases have been reported in the English medical literature. Here, for the first time in Asia, we report another case of chronic intractable diarrhea caused by gastrointestinal mastocytosis. The patient was a 70-year-old male with chronic intractable diarrhea for 3 months; the cause of the diarrhea remained obscure even after exhaustive evaluation. However, biopsy specimens from the jejunum were found to have increased mast cell infiltration, and the patient was successfully treated with antihistamines.

Citations

Citations to this article as recorded by  

• Mastocytic Enterocolitis: An Overlooked Diagnosis for Unexplained Chronic Diarrhea in a Patient With Colon Polyps and a Family History of Colon Cancer
  Leeann Hu, Liliana Franco, Jignesh Parikh, Vania Zayat
  Cureus.2023;[Epub]     CrossRef
• Systemic Mastocytosis: A Rare Cause of Diarrhea
  Leonard Hamera, Andrew M Santos, Sean-Patrick A Prince, Sreekanth Chandrupatla, Jeffrey Jordan
  Cureus.2020;[Epub]     CrossRef
• Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review
  Vivian C. Nanagas, Anna Kovalszki
  Clinical Reviews in Allergy & Immunology.2019; 57(2): 194.     CrossRef
• Mastocytosis
  Jingtao Chen, Patrick Brady, Jay Mamel
  The Nurse Practitioner.2019; 44(8): 17.     CrossRef
• The roles of mast cells in allergic inflammation and mast cell-related disorders
  Hee-Kyoo Kim
  Allergy, Asthma & Respiratory Disease.2017; 5(5): 248.     CrossRef

Pseudomembranous colitis (PMC) is a nosocomial and opportunistic infection caused by Clostridium difficile. PMC is related to the use of antibiotics leading to intestinal dysbiosis and an overgrowth of C. difficile. Metronidazole or vancomycin is considered to be the standard therapy for the management of PMC. However, PMC has a 15%–30% recurrence rate and can be refractory to standard treatments, resulting in morbidity and mortality. Here we describe a patient who experienced refractory PMC who was treated with fecal microbiota transplantation. A 69-year-old woman was admitted to the hospital with consistent abdominal pain and diarrhea, which had been present for 5 months. She was diagnosed with PMC by colonoscopy and tested positive for C. difficile toxin. Even though she took metronidazole for 10 days, followed by vancomycin for 4 weeks, her symptoms did not improve. Because of her recurrent and refractory symptoms, we decided to perform fecal microbiota transplantation. Fifty grams of fresh feces from a donor were obtained on the day of the procedure, mixed with 500 mL of normal saline, and then filtered. The filtered solution was administered to the patient's colon using a colonoscope. After the procedure, her symptoms rapidly improved and a follow-up colonoscopy showed that the PMC had resolved without recurrence.

Citations

Citations to this article as recorded by  

• Fecal microbiota transplantation: present and future
  Ra Ri Cha, Irene Sonu
  Clinical Endoscopy.2025; 58(3): 352.     CrossRef
• Fecal Microbiota Transplantation for Fulminant Clostridioides Difficile Infection: A Combined Medical and Surgical Case Series
  Ellen J Spartz, Mina Estafanos, Reema Mallick, Wolfganag Gaertner, Victor Vakayil, Cyrus Jahansouz, Rishav Aggarwal, Sayeed Ikramuddin, Alexander Khoruts, James V Harmon
  Cureus.2023;[Epub]     CrossRef
• Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
  Jongbeom Shin, Jung-Hwan Lee, Soo-Hyun Park, Boram Cha, Kye Sook Kwon, Hyungkil Kim, Yong Woon Shin
  Biomedicines.2022; 10(10): 2404.     CrossRef
• The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model
  Qiaomai Xu, Shumeng Zhang, Jiazheng Quan, Zhengjie Wu, Silan Gu, Yunbo Chen, Beiwen Zheng, Longxian Lv, Lanjuan Li
  Applied Microbiology and Biotechnology.2022; 106(19-20): 6689.     CrossRef
• The gut microbiota and gut disease
  Sasha R. Fehily, Chamara Basnayake, Emily K. Wright, Michael A. Kamm
  Internal Medicine Journal.2021; 51(10): 1594.     CrossRef
• RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
  Jung Hoon Song, You Sun Kim
  Gut and Liver.2019; 13(1): 16.     CrossRef
• Clostridium difficile in Asia: Opportunities for One Health Management
  Deirdre A. Collins, Thomas V. Riley
  Tropical Medicine and Infectious Disease.2018; 4(1): 7.     CrossRef
• Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation
  Yvette H. van Beurden, Max Nieuwdorp, Pablo J. E. J. van de Berg, Chris J. J. Mulder, Abraham Goorhuis
  Therapeutic Advances in Gastroenterology.2017; 10(4): 373.     CrossRef
• Fecal microbiota transplant in severe and severe-complicatedClostridium difficile: A promising treatment approach
  Monika Fischer, Brian Sipe, Yao-Wen Cheng, Emmalee Phelps, Nicholas Rogers, Sashidhar Sagi, Matthew Bohm, Huiping Xu, Zain Kassam
  Gut Microbes.2017; 8(3): 289.     CrossRef
• Fecal Microbiota Transplantation for Refractory and RecurrentClostridium difficileInfection: A Case Series of Nine Patients
  Byoung Wook Bang, Jin-Seok Park, Hyung Kil Kim, Yong Woon Shin, Kye Sook Kwon, Hea Yoon Kwon, Ji Hyeon Baek, Jin-Soo Lee
  The Korean Journal of Gastroenterology.2017; 69(4): 226.     CrossRef

The rates and severity of Clostridium difficile infections, including pseudomembranous colitis, have increased markedly. However, there are few effective treatments for refractory or recurrent C. difficile infections and the outcomes are poor. Fecal microbiota transplantation is becoming increasingly accepted as an effective and safe intervention in patients with recurrent disease, likely due to the restoration of a disrupted microbiome. Cure rates of >90% are being consistently reported from multiple centers. We cured a case of severe refractory C. difficile infection with fecal microbiota transplantation in a patient colonized by vancomycin-resistant enterococcus.

Citations

Citations to this article as recorded by  

• The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
  Rohma Ghani, Benjamin H. Mullish, Lauren A. Roberts, Frances J. Davies, Julian R. Marchesi
  Gut Microbes.2022;[Epub]     CrossRef
• Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile
  Mariachiara Mengoli, Monica Barone, Marco Fabbrini, Federica D’Amico, Patrizia Brigidi, Silvia Turroni
  Genes.2022; 13(12): 2200.     CrossRef
• Colonization Dynamics of Multidrug-Resistant Klebsiella pneumoniae Are Dictated by Microbiota-Cluster Group Behavior over Individual Antibiotic Susceptibility: A Metataxonomic Analysis
  János Juhász, Balázs Ligeti, Márió Gajdács, Nóra Makra, Eszter Ostorházi, Ferenc Balázs Farkas, Balázs Stercz, Ákos Tóth, Judit Domokos, Sándor Pongor, Dóra Szabó
  Antibiotics.2021; 10(3): 268.     CrossRef
• Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis
  Catherine M Cappetto
  American Journal of Health-System Pharmacy.2021; 78(15): 1374.     CrossRef
• Fecal microbiota transplantation for antibiotic resistant bacteria decolonization
  Sophie Amrane, Jean-Christophe Lagier
  Human Microbiome Journal.2020; 16: 100071.     CrossRef
• Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis
  V. Tavoukjian
  Journal of Hospital Infection.2019; 102(2): 174.     CrossRef
• Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria
  Benjamin Davido, Rui Batista, Aurélien Dinh, Pierre de Truchis, E.M. Terveer, Bruce Roberts, Ed J. Kuijper, Silvia Caballero
  International Journal of Antimicrobial Agents.2019; 53(5): 553.     CrossRef
• RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
  Jung Hoon Song, You Sun Kim
  Gut and Liver.2019; 13(1): 16.     CrossRef
• Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review
  S. Saha, R. Tariq, P.K. Tosh, D.S. Pardi, S. Khanna
  Clinical Microbiology and Infection.2019; 25(8): 958.     CrossRef
• Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives
  Livia Gargiullo, Federica Del Chierico, Patrizia D’Argenio, Lorenza Putignani
  Frontiers in Microbiology.2019;[Epub]     CrossRef
• Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection
  Young Kyung Yoon, Jin Woong Suh, Eun-Ji Kang, Jeong Yeon Kim
  Annals of Medicine.2019; 51(7-8): 379.     CrossRef
• The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions
  Michael H Woodworth, Mary K Hayden, Vincent B Young, Jennie H Kwon
  Open Forum Infectious Diseases.2019;[Epub]     CrossRef
• Design and application of oral colon administration system
  Hao Cheng, Shiyu Huang, Gangliang Huang
  Journal of Enzyme Inhibition and Medicinal Chemistry.2019; 34(1): 1590.     CrossRef
• The Intestinal Microbiota as a Reservoir and a Therapeutic Target to Fight Multi-Drug-Resistant Bacteria: A Narrative Review of the Literature
  Andrea Aira, Csaba Fehér, Elisa Rubio, Alex Soriano
  Infectious Diseases and Therapy.2019; 8(4): 469.     CrossRef
• Intestinal microbiota and antibiotic resistance: Perspectives and solutions
  Climent Casals-Pascual, Andrea Vergara, Jordi Vila
  Human Microbiome Journal.2018; 9: 11.     CrossRef
• The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms
  Srinivasa Nithin Gopalsamy, Michael H. Woodworth, Tiffany Wang, Cynthia T. Carpentieri, Nirja Mehta, Rachel J. Friedman-Moraco, Aneesh K. Mehta, Christian P. Larsen, Colleen S. Kraft
  The American Journal of the Medical Sciences.2018; 356(5): 433.     CrossRef
• Mechanisms of antimicrobial resistance among hospital-associated pathogens
  Ayesha Khan, William R. Miller, Cesar A. Arias
  Expert Review of Anti-infective Therapy.2018; 16(4): 269.     CrossRef
• The commensal microbiota exacerbate infectious colitis in stressor-exposed mice
  Jeffrey D. Galley, Nicola M. Parry, Brian M.M. Ahmer, James G. Fox, Michael T. Bailey
  Brain, Behavior, and Immunity.2017; 60: 44.     CrossRef
• Microbial approaches for targeting antibiotic‐resistant bacteria
  Wing Fei Wong, Marina Santiago
  Microbial Biotechnology.2017; 10(5): 1047.     CrossRef
• Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
  Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, Courtney Jones
  Open Forum Infectious Diseases.2016;[Epub]     CrossRef
• Can Fecal Microbiota Transplantation (FMT) Eradicate Fecal Colonization With Vancomycin-Resistant Enterococci (VRE)?
  Kyung Mok Sohn, Shinhye Cheon, Yeon-Sook Kim
  Infection Control & Hospital Epidemiology.2016; 37(12): 1519.     CrossRef
• Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
  Hyun Ho Choi, Young-Seok Cho
  Clinical Endoscopy.2016; 49(3): 257.     CrossRef